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TARGETING IN SITU AND IMAGING MULTIPLE INFLAMMATORY BIOMARKERS
WITH QUANTUM DOTS IN DSS MODEL OF COLITIS
Amolkumar Karwa1, Elizabeth Papazoglou1, Kambiz Pourrezaei1, Som Tyagi2, Sreekant Murthy3
1School of Biomedical Engineering, Drexel University, Philadelphia, PA   2 Department of Physics, Drexel University, Philadelphia, PA  3Drexel University College of Medicine, Philadelphia, PA
Develop appropriate biomarkers for quantification of inflammation.
Demonstrate the use of Quantum Dots (QDs) conjugated to antibodies
against Myeloperoxidase (MPO), Interleukin-1 (IL-1a) and Tumor
Necrosis Factor (TNF-a)  to detect and quantify acute inflammation in
the DSS model of colitis.
• Current measurement techniques for extracting MPO, IL-1a and TNFa to
monitor disease progression are excruciatingly cumbersome, time
consuming, and inefficient.
• We have developed an easy to use, nanosize based fluorescence assay
using antibody-bound Quantum Dots (QDs) to follow disease progression
and its response to treatment with therapeutic agents.
• QDs are fluorescent nanosize semiconductor particles with a size
tunable emission from 495 nm to 705 nm.
• QDs offer advantages of high quantum yield, narrow emission spectrum,
and extreme photostability, making them great tools for dynamic
monitoring of  disease progression markers
INTRODUCTION
Figure1: Size tunable
emission of QDs
Figure2: Extinction and
Emission Plot for QDs
OBJECTIVE
MATERIALS & METHODS
Animal Studies and Imaging for multiple markers
   Dextran Sulfate Sodium (DSS) model of colitis
• Colitis was induced by feeding 4% DSS ad libitum and
daily monitoring of Disease Activity Index (DAI) was
performed.
• Animals were sacrificed depending on the DAI.
• QD conjugates were locally introduced (150nM) in the
colon for 15 minutes.
• After 15 minutes, colon was washed, sectioned,
processed and imaged under confocal microscope.
Parallel histo- pathological sections were stained with
H&E for comparison.
Figure 3. Surgical
preparation for
introduction of QDs
in the colon of a
mouse
RESULTS AND DISCUSSIONS
Adjoining images are from various days in DSS induced colitis
model. Images 4A & 4B show the fluorescence and H&E stained
images on the Day3 of DSS feed. On Day3 there is minimal
inflammation and hence minimal expression of MPO. On Day5
there is increased inflammation, shortening of crypts (Image 4D)
and increased intensity of MPO expression (Image 4C). On Day8
animal showed florid inflammation, ulceration, total loss of crypts
(Image 4F) and hence even more intense labeling of the tissue
with QDs (Image 4E).
DSS model of colitis : Targeting MPO with QD655-MPO conjugates
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DSS model of colitis : Testing the specificity of the QD conjugates
• QD- Anti-testosterone AB to test specificity of
assay
• Non-specific antibody is not detected in the lamina
propria
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Figure7a: DAI increases with QD flow
intensity.  Severity of inflammation is
proportional to intensity of targeted
biomarker
Figure7b: Flourescence increases with
Disease Time Period (DTP). Severity of
inflammation is proportional to intensity of
targeted biomarker
DSS model of colitis : Targeting IL1α, MPO and TNFα with QD conjugates
Images depict targeting and simultaneous imaging of three
different markers Il1-a, MPO and TNFα in the acute phase of
DSS model of colitis. Images 8a-8r show increasing presence of
markers with the increase in severity of inflammation. Image 8r
shows selective targeting of these three markers in a lymphoid
follicle.
  CONCLUSIONS
• Quantum dots labeled with antibodies were
successfully used in situ to detect biomarkers of
inflammation in an established model of
experimental colitis.
• Animal studies showed that the intensity of
biomarkers correlated well with the disease
severity and progression.
• The developed assay is specific: QD conjugates
to non-specific antibody failed to show any binding
in the crypts of lamina propria in diseased animals.
• QD conjugates were able to target multiple
biomarkers in vivo in the DSS model of colitis.
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